Reckitt Benckiser Posts Q1 2025 Results, Driven by Emerging Markets and Powerbrands

Core Reckitt delivers 3.1% like-for-like net revenue growth, led by double-digit gains in Intimate Wellness and Germ Protection.

Team Kalkine | 23 April 2025

GSK plc (LSE/NYSE: GSK) Receives CDC Recommendation for Penmenvy in Adolescent Meningococcal Vaccination

GSK plc (LSE/NYSE: GSK) has received a significant step forward in the U.S. vaccination landscape, as the CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of Penmenvy, a combined meningococcal vaccine. Penmenvy, which protects against meningococcal groups A, B, C, …

Team Kalkine | 17 April 2025

Assura Agrees to £1.6 Billion Cash Acquisition by Sana Bidco

Highlights

Team Kalkine | 09 April 2025

ANGLE plc (AIM: AGL OTCQX: ANPCY) Completes Key Assays Development for AstraZeneca and Eisai

ANGLE plc (AIM:AGL OTCQX:ANPCY), a leading liquid biopsy company known for its innovative circulating tumor cell (CTC) solutions, has announced the successful completion of its development work for two significant assays with global pharmaceutical companies AstraZeneca and Eisai. ANGLE has now completed the development …

Team Kalkine | 21 March 2025

Healthcare

Reckitt Benckiser Posts Q1 2025 Results, Driven by Emerging Markets and Powerbrands

GSK plc (LSE/NYSE: GSK) Receives CDC Recommendation for Penmenvy in Adolescent Meningococcal Vaccination

Assura Agrees to £1.6 Billion Cash Acquisition by Sana Bidco

ANGLE plc (AIM: AGL OTCQX: ANPCY) Completes Key Assays Development for AstraZeneca and Eisai

Latest News

Is LSE:IOF One Of The Strongest Commodity-Linked Growth Stories On AIM?

Can Pantheon Resources Deliver on Its Alaska Oil Potential?

Is Altona Rare Earths a Hidden Rare Earth Opportunity?

Are UK Industrial Stocks Like Castings Undervalued?

How Does Market Volatility Affect CMCX Revenue?

Can Nanoco Survive as a Microcap Technology Stock?